Eli Lilly Reports $303 Million in Special Charges for Quarter Ended Sept. 30
A SEC filing says Eli Lilly recognized $303 million in asset impairment, restructuring and other special charges during the three months ended Sept. 30.
A SEC filing says Eli Lilly recognized $303 million in asset impairment, restructuring and other special charges during the three months ended Sept. 30.